Abbott, Novo Nordisk Partner Up on Integrated Digital Solution for Diabetic Patients

March 1, 2019
Pharmaceutical Technology Editors

Abbott and Novo Nordisk have entered into a non-exclusive partnership aimed at providing an integrated digital solution for diabetic patients using insulin,

Abbott and Novo Nordisk have entered into a non-exclusive partnership aimed at providing an integrated digital solution for diabetic patients using insulin, it was revealed in a Feb. 20, 2019 press release.

The digital solution will comprise the integration of insulin dose data from Novo Nordisk pre-filled connected pens directly into the digital health tools that are compatible with the FreeStyle Libre system (FreeStyle LibreLink mobile app and LibreView cloud-based system). It is hoped that through integrating products, patients and healthcare professionals will be able to gain more information and hence will allow for more informed decisions to be made about treatment and health outcomes.

“Lack of reliable information is a cause of huge frustration for many people with diabetes and their doctors,” said Anders Dyhr Toft, corporate vice-president, Commercial Innovation, Novo Nordisk. “Together with partners like Abbott, our connected pens will give healthcare professionals a better understanding of a patient's individual diabetes management and can help people with diabetes feel more confident in their treatment.”

“It is our aim at Abbott to continuously provide life-changing technology to people living with diabetes,” added Jared Watkin, senior vice-president, Diabetes Care, Abbott. “Diabetes is a time-intensive condition to manage. People with diabetes must make a variety of decisions every single day about their glucose monitoring, nutrition, insulin and medication intake. By enabling insulin dosing data from Novo Nordisk’s connected pens to be shared with our digital health tools, we'll be able to help further eliminate those daily hassles for people, so they have more time to live a fuller, healthier life.”

Source: Novo Nordisk